Physical and hormonal evaluation of transsexual patients

A longitudinal study

Walter Meyer, Alice Webb, Charles A. Stuart, Jordan W. Finkelstein, Barbara Lawrence, Paul A. Walker

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

The physical and hormonal characteristics of 60 male-to-female transsexuals and 30 female-to-male transsexuals were measured before or during treatment with commonly used forms and dosages of hormones. Only two patients (both female-to-male) had either a congenital defect in hormonal production or abnormal genital development. Patients were seen at 3- to 6-month intervals for an average of 18 months. The response to therapy was examined over time; physical parameters, hormonal concentrations, liver function tests, lipids, and glucose were measured. Three patients were changed from ethinyl estradiol to conjugated estrogen because of liver enzyme elevations. Ethinyl estradiol (0.1-0.5 mg/day) was equal to conjugated estrogen (7.5-10 mg/day) in its ability to suppress testosterone and gonadotropins and to promote breast growth. Maximum breast growth required 2 years of therapy. During treatment with testosterone, female-to-male transsexuals had a significant mild elevation of cholesterol and triglyceride. The female-to-male transsexuals receiving testosterone cypionate, 200 mg every 2 weeks, ceased to have menstrual periods and became progressively masculinized. A mean maximal clitoral length of 4.6 cm which achieved by 1 year of therapy. Based on the data generated by this study, we recommend as hormonal therapy 0.1-0.5 mg/day of ethinyl estradiol or 7.5-10 mg/day of conjugated estrogen for male-to-female transsexuals, and intramuscular testosterone cypionate, 200 mg every 2 weeks, for female-to-male transsexuals.

Original languageEnglish (US)
Pages (from-to)121-138
Number of pages18
JournalArchives of Sexual Behavior
Volume15
Issue number2
DOIs
StatePublished - Apr 1986

Fingerprint

Longitudinal Studies
Conjugated (USP) Estrogens
Ethinyl Estradiol
Testosterone
Breast
Therapeutics
Liver Function Tests
Dosage Forms
Growth
Longitudinal Study
Evaluation
Transsexual
Physical
Gonadotropins
Triglycerides
Cholesterol
Hormones
Lipids
Glucose
Therapy

Keywords

  • breast
  • clitoris
  • estrogen
  • hormone
  • testes
  • testosterone
  • transsexual

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychology(all)

Cite this

Meyer, W., Webb, A., Stuart, C. A., Finkelstein, J. W., Lawrence, B., & Walker, P. A. (1986). Physical and hormonal evaluation of transsexual patients: A longitudinal study. Archives of Sexual Behavior, 15(2), 121-138. https://doi.org/10.1007/BF01542220

Physical and hormonal evaluation of transsexual patients : A longitudinal study. / Meyer, Walter; Webb, Alice; Stuart, Charles A.; Finkelstein, Jordan W.; Lawrence, Barbara; Walker, Paul A.

In: Archives of Sexual Behavior, Vol. 15, No. 2, 04.1986, p. 121-138.

Research output: Contribution to journalArticle

Meyer, W, Webb, A, Stuart, CA, Finkelstein, JW, Lawrence, B & Walker, PA 1986, 'Physical and hormonal evaluation of transsexual patients: A longitudinal study', Archives of Sexual Behavior, vol. 15, no. 2, pp. 121-138. https://doi.org/10.1007/BF01542220
Meyer W, Webb A, Stuart CA, Finkelstein JW, Lawrence B, Walker PA. Physical and hormonal evaluation of transsexual patients: A longitudinal study. Archives of Sexual Behavior. 1986 Apr;15(2):121-138. https://doi.org/10.1007/BF01542220
Meyer, Walter ; Webb, Alice ; Stuart, Charles A. ; Finkelstein, Jordan W. ; Lawrence, Barbara ; Walker, Paul A. / Physical and hormonal evaluation of transsexual patients : A longitudinal study. In: Archives of Sexual Behavior. 1986 ; Vol. 15, No. 2. pp. 121-138.
@article{08788b9b141f47c4a2f92c4188849fac,
title = "Physical and hormonal evaluation of transsexual patients: A longitudinal study",
abstract = "The physical and hormonal characteristics of 60 male-to-female transsexuals and 30 female-to-male transsexuals were measured before or during treatment with commonly used forms and dosages of hormones. Only two patients (both female-to-male) had either a congenital defect in hormonal production or abnormal genital development. Patients were seen at 3- to 6-month intervals for an average of 18 months. The response to therapy was examined over time; physical parameters, hormonal concentrations, liver function tests, lipids, and glucose were measured. Three patients were changed from ethinyl estradiol to conjugated estrogen because of liver enzyme elevations. Ethinyl estradiol (0.1-0.5 mg/day) was equal to conjugated estrogen (7.5-10 mg/day) in its ability to suppress testosterone and gonadotropins and to promote breast growth. Maximum breast growth required 2 years of therapy. During treatment with testosterone, female-to-male transsexuals had a significant mild elevation of cholesterol and triglyceride. The female-to-male transsexuals receiving testosterone cypionate, 200 mg every 2 weeks, ceased to have menstrual periods and became progressively masculinized. A mean maximal clitoral length of 4.6 cm which achieved by 1 year of therapy. Based on the data generated by this study, we recommend as hormonal therapy 0.1-0.5 mg/day of ethinyl estradiol or 7.5-10 mg/day of conjugated estrogen for male-to-female transsexuals, and intramuscular testosterone cypionate, 200 mg every 2 weeks, for female-to-male transsexuals.",
keywords = "breast, clitoris, estrogen, hormone, testes, testosterone, transsexual",
author = "Walter Meyer and Alice Webb and Stuart, {Charles A.} and Finkelstein, {Jordan W.} and Barbara Lawrence and Walker, {Paul A.}",
year = "1986",
month = "4",
doi = "10.1007/BF01542220",
language = "English (US)",
volume = "15",
pages = "121--138",
journal = "Archives of Sexual Behavior",
issn = "0004-0002",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Physical and hormonal evaluation of transsexual patients

T2 - A longitudinal study

AU - Meyer, Walter

AU - Webb, Alice

AU - Stuart, Charles A.

AU - Finkelstein, Jordan W.

AU - Lawrence, Barbara

AU - Walker, Paul A.

PY - 1986/4

Y1 - 1986/4

N2 - The physical and hormonal characteristics of 60 male-to-female transsexuals and 30 female-to-male transsexuals were measured before or during treatment with commonly used forms and dosages of hormones. Only two patients (both female-to-male) had either a congenital defect in hormonal production or abnormal genital development. Patients were seen at 3- to 6-month intervals for an average of 18 months. The response to therapy was examined over time; physical parameters, hormonal concentrations, liver function tests, lipids, and glucose were measured. Three patients were changed from ethinyl estradiol to conjugated estrogen because of liver enzyme elevations. Ethinyl estradiol (0.1-0.5 mg/day) was equal to conjugated estrogen (7.5-10 mg/day) in its ability to suppress testosterone and gonadotropins and to promote breast growth. Maximum breast growth required 2 years of therapy. During treatment with testosterone, female-to-male transsexuals had a significant mild elevation of cholesterol and triglyceride. The female-to-male transsexuals receiving testosterone cypionate, 200 mg every 2 weeks, ceased to have menstrual periods and became progressively masculinized. A mean maximal clitoral length of 4.6 cm which achieved by 1 year of therapy. Based on the data generated by this study, we recommend as hormonal therapy 0.1-0.5 mg/day of ethinyl estradiol or 7.5-10 mg/day of conjugated estrogen for male-to-female transsexuals, and intramuscular testosterone cypionate, 200 mg every 2 weeks, for female-to-male transsexuals.

AB - The physical and hormonal characteristics of 60 male-to-female transsexuals and 30 female-to-male transsexuals were measured before or during treatment with commonly used forms and dosages of hormones. Only two patients (both female-to-male) had either a congenital defect in hormonal production or abnormal genital development. Patients were seen at 3- to 6-month intervals for an average of 18 months. The response to therapy was examined over time; physical parameters, hormonal concentrations, liver function tests, lipids, and glucose were measured. Three patients were changed from ethinyl estradiol to conjugated estrogen because of liver enzyme elevations. Ethinyl estradiol (0.1-0.5 mg/day) was equal to conjugated estrogen (7.5-10 mg/day) in its ability to suppress testosterone and gonadotropins and to promote breast growth. Maximum breast growth required 2 years of therapy. During treatment with testosterone, female-to-male transsexuals had a significant mild elevation of cholesterol and triglyceride. The female-to-male transsexuals receiving testosterone cypionate, 200 mg every 2 weeks, ceased to have menstrual periods and became progressively masculinized. A mean maximal clitoral length of 4.6 cm which achieved by 1 year of therapy. Based on the data generated by this study, we recommend as hormonal therapy 0.1-0.5 mg/day of ethinyl estradiol or 7.5-10 mg/day of conjugated estrogen for male-to-female transsexuals, and intramuscular testosterone cypionate, 200 mg every 2 weeks, for female-to-male transsexuals.

KW - breast

KW - clitoris

KW - estrogen

KW - hormone

KW - testes

KW - testosterone

KW - transsexual

UR - http://www.scopus.com/inward/record.url?scp=0022516507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022516507&partnerID=8YFLogxK

U2 - 10.1007/BF01542220

DO - 10.1007/BF01542220

M3 - Article

VL - 15

SP - 121

EP - 138

JO - Archives of Sexual Behavior

JF - Archives of Sexual Behavior

SN - 0004-0002

IS - 2

ER -